Owkin signs AI drug discovery deal with Boehringer for cancer, immunology. 02 Sep 2026 08:03PM (Updated: 02 Sep 2026 10:47PM) Add CNA as a trusted source to help Google better understand and surface our content in search results. Sept 2: AI company Owkin said on Wednesday it has signed a licensing deal with Germany's Boehringer Ingelheim, giving the drugmaker access to its AI research platform and patient data to speed up discovery of drugs for cancer and immunity-related diseases. The deal adds Boehringer to a growing list of drugmakers using Owkin's AI technology, "K Pro". AstraZeneca licensed it in May, while Sanofi expanded its partnership with a five-year agreement in June. Here are some more details: - The deal builds on the companies' pilot project in 2025, in which Owkin used its patient tumor samples and related biological datasets to help Boehringer prioritize potential drug targets, the AI company's CEO, Thomas Clozel, told Reuters. - Under the new pact, Owkin will license multimodal oncology data to Boehringer and will generate new data in immunology. - Owkin licenses, sources and generates patient data in collaboration with its global patient data network. - The companies did not disclose the financial terms of the agreement.

DeepCyte launches world's first single-cell mechanistic toxicity atlas as enterprise pharma pilots advance. Proprietary training dataset spanning 300,000 cells and ~100 compounds positions DeepCyte to transform preclinical toxicology with mechanism-based prediction Wilmington, DE and Copenhagen, Denmark /PRNewswire/ - DeepCyte Inc., a techbio company building AI toxicology tools for drug development, today announced the launch of DeeTox Atlas(TM), the world's first single-cell metabolomic reference atlas of drug toxicity mechanisms. Enterprise pilot programs with global pharmaceutical companies begin in the coming months. DeeTox Atlas(TM) is a foundation dataset built from two independent single-cell metabolomics perturbation studies, spanning approximately 100 toxicant compounds, 300,000 cells, and ~500 metabolites per cell - over 3,000 single-cell measurements per compound across six biological replicates. Each compound is mapped to a curated four-level hierarchy of toxicity mechanisms anchored to established Adverse Outcome Pathways (AOPs). Rather than generating new wet-lab data for every compound, DeepCyte trains a foundation model capable of predicting toxicity mechanisms for compounds it has never measured. As the atlas expands, the platform becomes increasingly scalable, reducing laboratory dependence while improving predictive performance. "AI in toxicology is only as good as the biological data it learns from. DeeTox Atlas lets us find subtle molecular patterns tied to key toxicity mechanisms - patterns our validation studies show are expressed in small subpopulations of cells and are effectively invisible to methods lacking single-cell resolution - and turn them into predictive models," said Theodore Alexandrov, Co-Founder and CEO of DeepCyte. "Our vision is to move toxicology from reactive laboratory testing toward predictive, mechanism-based AI that surfaces and explains safety liabilities earlier in drug discovery." The Atlas will expand with more compounds, mechanisms, and biochemical and clinical data, making predictions more actionable for toxicologists, medicinal chemists, and safety scientists. DeepCyte has also appointed Mona Lakkis as Senior Vice President of Partnerships. Formerly Senior Vice President & General Manager at Owkin, Lakkis will lead enterprise commercialization as DeepCyte advances pilots with three of the top 20 pharmaceutical companies. About DeepCyte DeepCyte is an AI-powered techbio company developing predictive toxicology solutions for drug discovery. By training mechanistic AI models on proprietary single-cell data, DeepCyte helps pharmaceutical companies predict toxicity mechanisms earlier, accelerating safer and more efficient therapeutic discovery. Like what you are reading?

Owkin to integrate Kognitic's clinical trial data into K Pro through new collaboration. NEW YORK & PARIS - Owkin, the agentic AI company pioneering Biological Artificial SuperIntelligence to revolutionize drug discovery and development, today announced a data collaboration with Kognitic to integrate Kognitic's clinical trial data into K Pro, Owkin's AI Scientist. The collaboration will initially focus on oncology and immunology, with the potential to expand into additional therapeutic areas and datasets over time. Kognitic structures global clinical trial signals into a normalized, decision-ready evidence layer for commercial, medical, and BD teams. These signals span trial registries, pipeline timelines, and competitive landscape data. Through this collaboration, Kognitic clinical data will be accessible directly within K Pro, giving decision-making teams a single source of data across fragmented feeds. K Pro combines multimodal patient data with specialized biological, agentic AI systems to support each stage of the pharmaceutical value chain. Bringing Kognitic's clinical trial data into that layer extends K Pro's reach into competitive intelligence and portfolio-decision use cases, alongside its existing biological and multimodal data capabilities. Thomas Clozel, MD, Co-founder and CEO, Owkin: Pharmaceutical decision-making depends on the best, structured, real-time data. Bringing Kognitic's clinical trial data into K Pro gives its partners a faster, more complete picture the moment they need it. Kimon Lounis, Director of Commercial Strategy & Partnerships, Kognitic: This partnership is a major milestone for Kognitic and for how clinical trial data can power advanced AI in life sciences. By bringing Kognitic's clinical trial data into K Pro, Owkin can support Owkin's AI Scientist with richer evidence for agentic workflows and biological reasoning. Jaseem Mahmmdla, Co-Founder and CEO, Kognitic: The next generation of AI in life sciences will be built through partnerships that combine best-in-class intelligence. Owkin has built an exceptional platform with K Pro, and together Owkin is bringing trusted clinical trial data into a unified environment to help pharmaceutical teams make faster, more informed decisions. About Owkin. Owkin is an agentic AI company pioneering Biological Artificial Superintelligence to solve problems in biology too challenging for human researchers alone. Owkin builds K Pro - an AI scientist that works alongside pharmaceutical research teams to power discovery and strategic decision-making. K Pro autonomously orchestrates a suite of AI skills and tools to decode complex biology and accelerate research, with scientists shaping every hypothesis, decision, and discovery. K Pro is built on Owkin's unrivalled multimodal patient data network, state-of-the-art AI for biology, and a decade of experience working hand-in-hand with pharmaceutical partners.